Stockwatch: BioMarin's Biggest Liabilities
This article was originally published in Scrip
Executive Summary
In an amalgamation of human resources jargon and accounting-speak, many companies describe their employees as their 'greatest asset'. In a similar but inverse metaphor, when many investors think of risk, they only think of the potential to lose money, rather than the chances of making excess positive returns. Despite losing only 13.6% of its value in the past two weeks (over which time admittedly the NASDAQ Biotech Index gained 4.5%), BioMarin Pharmaceutical, Inc. has demonstrated that a company's employees can also be its biggest liability.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.